Li Lin
Impact in
- Oncology top 2%
- Cytokine Signaling Pathways and Interactions
- COVID-19 and healthcare impacts
- Cancer Cells and Metastasis
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Oncology 31
- Cytokine Signaling Pathways and Interactions 19
- Cancer Cells and Metastasis 5
- Co-authors
- Jiayuh LinChenglong LiPui‐Kai LiLian YangDehan LiuXiang ZhouJuan WuBixi Li
- Journals
- European Journal of Pharmacology (4 papers)Oncotarget (4 papers)PLoS ONE (4 papers)Cancer Research (3 papers)Frontiers in Cardiovascular Medicine (3 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Li Lin
112 papers receiving 5.0k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Oncology 1.5k
- Infectious Diseases 1.0k
- Obstetrics and Gynecology 374
- Toxicology 159
- Neurology 589
Countries citing papers authored by Li Lin
This map shows the geographic impact of Li Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Lin more than expected).
Fields of papers citing papers by Li Lin
This network shows the impact of papers produced by Li Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Lin. The network helps show where Li Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Li Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 2 | |
| 4 | 2023 | 3 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 84 | |
| 7 | 2023 | 1 | |
| 8 | 2021 | 4 | |
| 9 | 2020 | 25 | |
| 10 | 2020 | 8 | |
| 11 | 2015 | 35 | |
| 12 | 2015 | 10 | |
| 13 | 2013 | 5 | |
| 14 | 2013 | 60 | |
| 15 | 2011 | 251 | |
| 16 | 2011 | 101 | |
| 17 | 2010 | 197 | |
| 18 | 2009 | 75 | |
| 19 | 2007 | 14 | |
| 20 | Synthesis and Characterization of Asymmetric Bis-Schiff Base Containing Thiocarbohydrazide | 2005 | 0 |
About Li Lin
Li Lin is a scholar working on Toxicology, Oncology, Infectious Diseases, Cancer Research and Hematology, having authored 113 papers that have together received 5.0k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (19 papers), COVID-19 Clinical Research Studies (9 papers), Protein Tyrosine Phosphatases (7 papers), Cardiac electrophysiology and arrhythmias (6 papers), Cancer Cells and Metastasis (5 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer Mechanisms and Therapy (5 papers) and RNA modifications and cancer (4 papers). The work is most often cited by research in Oncology (1.5k citations), Infectious Diseases (1.0k citations), Obstetrics and Gynecology (374 citations), Toxicology (159 citations) and Neurology (589 citations). Li Lin has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jiayuh Lin, Chenglong Li, Pui‐Kai Li, Lian Yang, Dehan Liu, Xiang Zhou, Juan Wu, Bixi Li, Mengda Xu and Xiaoyang Song. Their work appears in journals such as European Journal of Pharmacology, Oncotarget, PLoS ONE, Cancer Research and Frontiers in Cardiovascular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.